Achieve Life Sciences Closes $354M Private Placement, Eyes FDA Approval in H1 2027
ACHV has more than doubled off its 52-week low of $2.371.
Summary
Achieve Life Sciences closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from milestone-based warrants exercisable around FDA approval. This financing follows the June 2026 Complete Response Letter for cytisinicline, which raised no efficacy or safety concerns. The company has transitioned manufacturing to U.S.-based Adare Pharma Solutions and plans to resubmit the NDA in Q4 2026, targeting approval in the first half of 2027. New CEO Andrew Goldberg and six new board members bring commercial and financial expertise, with a commercial team already being built. The capital raise and leadership overhaul position the company for a potential U.S. launch, addressing prior going-concern risks. The upfront $180 million provides a clear runway through the resubmission and approval process.
At the time of this announcement, ACHV was trading at $6.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $684.7M. The 52-week trading range was $2.37 to $7.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.